Adipogen/anti-VEGFR-2 (human), mAb (EIC)/AG-20T-0108-C100/100 ?g
一抗
商品编号
AG-20T-0108-C100
品牌
Adipogen
公司
Adipogen
公司分类
Antibodies
Size
100 ?g
商品信息
More Information
Product Details
Synonyms
Vascular Endothelial Growth Factor Receptor-2; KDR; FLK-1
Product Type
Monoclonal Antibody
Properties
Clone
EIC
Isotype
Mouse IgG1
Immunogen/Antigen
Recombinant human soluble extracellular VEGFR-2.
Application
ELISA
:
(1-5μg/ml)
Flow Cytometry
: (2-10μg/ml)
Immunohistochemistry
: (6-30μg/ml)
Western Blot:
(2-5μg/ml)
Optimal conditions must be determined individually for each application.
Crossreactivity
Human
Specificity
The antibody will detect native human VEGFR-2/KDR in
ELISA
experiments and on the surface of different human cell types.
Purity
Protein G purified.
Purity Detail
Protein G purified.
Formulation
Lyophilized.
Reconstitution
Centrifuge vial prior to opening. Reconstitute with sterile water to a concentration of 0.1-1.0mg/ml.
Shipping and Handling
Shipping
BLUE ICE
Short Term Storage
+4°C
Long Term Storage
-20°C
Handling Advice
After opening, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Use/St
ABI
lity
Stable for at least 6 months after receipt when stored at -20°C.
Documents
MSD
S
Download PDF
Product Specification Sheet
Datasheet
Download PDF
Disruption of the precise balance of positive and negative molecular regulators of blood and lymphatic vessel growth can lead to myriad diseases. Although dozens of natural inhibitors of hemangiogenesis have been identified, an endogenous selective inhibitor of lymphatic vessel growth has not been previously described. A splice variant of the gene encoding vascular endothelial growth factor receptor-2 (VEGFR-2) that encodes a secreted form of the protein, designated endogenous soluble VEGFR-2 (esVEGFR-2/KDR) has been described. The endogenous soluble esKDR inhibits developmental and reparative lymphangiogenesis by blocking VEGF-C function. Tissue-specific loss of esKDR in mice induced, at birth, spontaneous lymphatic invasion of the normally alymphatic cornea and hyperplasia of skin lymphatics without affecting blood vasculature. Admi
NIST
ration of esKDR inhibited lymphangiogenesis but not hemangiogenesis induced by corneal suture injury or transplantation, enhanced corneal allograft survival and suppressed lymphangioma cellular proliferation. Naturally occurring esKDR thus acts as a molecular uncoupler of blood and lymphatic vessels; modulation of esKDR might have therapeutic effects in treating lymphatic vascular malformations, transplantation rejection and, potentially, tumor lymphangiogenesis and lymphedema.
Product References
Expression of vascular endothelial growth factor receptor-2 or Tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization: G. Nowak, et al.; Circulation
110
, 3699 (2004)
产品货号:5388.0